Clinical Trial Update: Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of a single IV infusion of XG-102 at 10, 40, and 80 µg/kg in healthy volunteers. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation

Drugs mentioned

• XG-102

Snippet

Sponsor: Xigen SA | Conditions: Inflammation | Phase 1 | Status: COMPLETED